OAB Study Astellas Plus Study 178-MA-1008
A phase 4, double–blind, randomized, placebo controlled, multi-center study to evaluate the efficacy, safety, and tolerability of Mirabegron in men with overactive bladder (OAB) symptoms while taking the alpha blocker Tamsulosin Hydrochloride for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) .
OAB Study LO-BOT CMO-US-URO-0470
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate an alternative injection paradigm for OnabotulinumtoxinA (BOTOX®) in the treatment of overactive bladder in patients with urinary incontinence (LO-BOT).
Dysport® Treatment of Urinary Incontinence in Adults Subjects with Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis – Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).
If you are interested in more information about any of our current clinical studies listed above, please contact 516-931-0041.